{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:31:34Z","timestamp":1793971894975,"version":"4.8.0"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:00:00Z","timestamp":1793923200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kazia Therapeutics","id":[{"id":"https:\/\/ror.org\/029p5cv63","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIH HCC SPORE in Breast Cancer","award":["P50 CA168504"],"award-info":[{"award-number":["P50 CA168504"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lili Billings Fund for Metastatic Breast Cancer Research","id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"name":"SEOM Research Fellowship 2024"},{"name":"CRIS Outback Fellowship Programme 2024"},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["CCR19609014"],"award-info":[{"award-number":["CCR19609014"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Human epidermal growth factor receptor 2 (HER2)\u2013positive breast cancer brain metastases (BCBM) frequently harbor PI3K\/AKT\/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with dual PI3K and mTOR inhibition. Our phase II trial evaluated paxalisib, a brain-penetrant dual PI3K\/mTOR inhibitor, combined with trastuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Eligible patients had active\/progressive HER2+ BCBM and could have received prior therapies; leptomeningeal disease was excluded. The trial included a safety run-in to determine the recommended phase II dose (RP2D), followed by expansion cohorts. The primary endpoint was confirmed central nervous system (CNS) objective response rate (ORR) per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria at the RP2D. Paired plasma and cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was analyzed using ultralow-pass whole-genome sequencing (ULP-WGS) and whole-exome sequencing (WES).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seventeen patients were treated (median age, 44 years; median 5 prior therapy lines). Paxalisib 30 mg daily plus trastuzumab was established as the RP2D. Among 12 patients treated at the RP2D, no confirmed CNS responses occurred [CNS ORR, 0%; 95% confidence interval (CI), 0%\u201326.5%], and the study closed for futility. The median overall survival (OS) was 16.5 months. Treatment was feasible, with a safety profile consistent with PI3K\/mTOR inhibition. Exploratory ctDNA analyses showed higher tumor fraction (TF) in CSF than plasma, with longitudinal changes in CSF TF paralleling CNS tumor burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Paxalisib combined with trastuzumab was feasible but did not meet the primary endpoint of CNS ORR in heavily pretreated HER2+ BCBM. Exploratory findings suggest that CSF-derived ctDNA may better capture tumor genomics and treatment response than plasma ctDNA in HER2+ BCBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The brain-penetrant dual PI3K\/mTOR inhibitor paxalisib plus trastuzumab showed minimal activity in heavily pretreated HER2+ BCBM. Paired liquid biopsy analyses demonstrated that CSF-derived ctDNA may better reflect tumor genomics and treatment response than plasma, supporting CSF for translational studies in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT03765983.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0571","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:55:14Z","timestamp":1792428914000},"page":"2619-2630","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-9825","authenticated-orcid":false,"given":"Elia","family":"Segui","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0068","authenticated-orcid":false,"given":"Jorge","family":"Gomez Tejeda Za\u00f1udo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute 4 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0622-683X","authenticated-orcid":false,"given":"Noah","family":"Graham","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 5 Department of Data Science, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8263-3314","authenticated-orcid":false,"given":"Patrick T.","family":"Kurnia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute 4 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-5490","authenticated-orcid":false,"given":"Andrea N.","family":"Perry","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, Massachusetts."},{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 5 Department of Data Science, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-6612","authenticated-orcid":false,"given":"Heather A.","family":"Parsons","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0213-8680","authenticated-orcid":false,"given":"Raechel","family":"Davis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1036-796X","authenticated-orcid":false,"given":"Molly K.","family":"DiLullo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0633-3151","authenticated-orcid":false,"given":"Jennifer A.","family":"Ligibel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-7076","authenticated-orcid":false,"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-775X","authenticated-orcid":false,"given":"Jing","family":"Ni","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 6 Department of Cancer Biology, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-1723","authenticated-orcid":false,"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[{"name":"7Yale Cancer Center, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5649-7229","authenticated-orcid":false,"given":"Adrienne G.","family":"Waks","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-5688","authenticated-orcid":false,"given":"Jean","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, Massachusetts."},{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 6 Department of Cancer Biology, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-7529","authenticated-orcid":false,"given":"Rinath M.","family":"Jeselsohn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-652X","authenticated-orcid":false,"given":"Jos\u00e9 P.","family":"Leone","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Medical Oncology, , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,11,6]]},"reference":[{"issue":"12_Supplement","key":"2026110608160652200_bib1","doi-asserted-by":"publisher","first-page":"P5-05-04","DOI":"10.1158\/1557-3265.sabcs24-p5-05-04","article-title":"Abstract P5-05-04: final results of a phase II trial evaluating paxalisib with trastuzumab for patients (pts) with HER2 positive metastatic breast cancer with active brain metastases","volume":"31","author":"Leone","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2026110608160652200_bib2","doi-asserted-by":"publisher","first-page":"ii35","DOI":"10.1093\/noajnl\/vdaf123.132","article-title":"TRLS-09 cerebrospinal fluid (CSF) and plasma circulating tumor DNA (CTDNA) for molecular profiling and monitoring of treatment response in a phase II trial of paxalisib for HER2-positive (HER2+) breast cancer brain metastases (BCBM)","volume":"7","author":"Segui","year":"2025","journal-title":"Neurooncol Adv"},{"key":"2026110608160652200_bib3","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026110608160652200_bib4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026110608160652200_bib5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/jnci\/djaf048","article-title":"Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients","volume":"117","author":"Sammons","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026110608160652200_bib6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026110608160652200_bib7","doi-asserted-by":"publisher","first-page":"CD003869","DOI":"10.1002\/14651858.CD003869.pub4","article-title":"Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases","volume":"1","author":"Tsao","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026110608160652200_bib8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026110608160652200_bib9","doi-asserted-by":"publisher","first-page":"101213","DOI":"10.1016\/j.esmoop.2023.101213","article-title":"Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry","volume":"8","author":"Riecke","year":"2023","journal-title":"ESMO Open"},{"key":"2026110608160652200_bib10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1159\/000518848","article-title":"The impact of stereotactic or whole brain radiotherapy on neurocognitive functioning in adult patients with brain metastases: a systematic review and meta-analysis","volume":"44","author":"van Grinsven","year":"2021","journal-title":"Oncol Res Treat"},{"key":"2026110608160652200_bib11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026110608160652200_bib12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"2026110608160652200_bib13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial\u2606","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"key":"2026110608160652200_bib14","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026110608160652200_bib15","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"2026110608160652200_bib16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026110608160652200_bib17","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"2026110608160652200_bib18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"2026110608160652200_bib19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"2026110608160652200_bib20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO-25-02643","article-title":"VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor-positive\/HER2\u2212\/PIK3CA wild-type advanced breast cancer","volume":"44","author":"Hurvitz","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026110608160652200_bib21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"2026110608160652200_bib22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res"},{"key":"2026110608160652200_bib23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"2026110608160652200_bib24","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/onc.2015.406","article-title":"PI3K-p110\u03b1 mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers","volume":"35","author":"Wang","year":"2016","journal-title":"Oncogene"},{"key":"2026110608160652200_bib25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdw246","article-title":"PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum","volume":"27","author":"Goel","year":"2016","journal-title":"Ann Oncol"},{"key":"2026110608160652200_bib26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajpath.2013.03.023","article-title":"Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases","volume":"183","author":"Hohensee","year":"2013","journal-title":"Am J Pathol"},{"key":"2026110608160652200_bib27","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.18632\/oncotarget.14047","article-title":"PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression","volume":"8","author":"Hohensee","year":"2017","journal-title":"Oncotarget"},{"key":"2026110608160652200_bib28","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/bcr3071","article-title":"Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases","volume":"13","author":"Adamo","year":"2011","journal-title":"Breast Cancer Res"},{"key":"2026110608160652200_bib29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nm.4120","article-title":"Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases","volume":"22","author":"Ni","year":"2016","journal-title":"Nat Med"},{"key":"2026110608160652200_bib30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"2026110608160652200_bib31","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","article-title":"First-in-human phase I study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma","volume":"26","author":"Wen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026110608160652200_bib32","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026110608160652200_bib33","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026110608160652200_bib34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026110608160652200_bib35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-017-4596-7","article-title":"Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy","volume":"168","author":"Pistilli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026110608160652200_bib36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2021.03.042","article-title":"Alpelisib in combination with everolimus \u00b1 exemestane in solid tumours: phase Ib randomised, open-label, multicentre study","volume":"151","author":"Curigliano","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026110608160652200_bib37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10549-018-4852-5","article-title":"LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases","volume":"171","author":"Van Swearingen","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026110608160652200_bib38","doi-asserted-by":"publisher","first-page":"1758835918807339","DOI":"10.1177\/1758835918807339","article-title":"Phase Ib\/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)","volume":"10","author":"Hurvitz","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2026110608160652200_bib39","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/S1470-2045(20)30556-8","article-title":"The genomic landscape of breast cancer brain metastases: a systematic review","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026110608160652200_bib40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41523-023-00550-1","article-title":"Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer","volume":"9","author":"Morganti","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"2026110608160652200_bib41","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0571\/3840293\/crc-26-0571.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/11\/2619\/3847022\/crc-26-0571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/11\/2619\/3847022\/crc-26-0571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:16:16Z","timestamp":1793970976000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/11\/2619\/789865\/Paxalisib-with-Trastuzumab-for-HER2-Positive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0571","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34937625","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937613","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937646","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937634","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937622","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937643","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937631","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937640","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937619","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937628","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937616","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34937637","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8823282","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}